ENDRA Life Sciences
NDRA | NASDAQ
$4.42
+$0.01 (+0.23%)
At close: Nov 16, 2026, 4:00 PM ET
$4.42
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:11 PM ET
ENDRA Life Sciences Company Profile
Company profile explainedCompany Profile
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Key Executives
| Name | Position |
|---|---|
| Alexander Y. Tokman | Chief Executive Officer & Chairman |
| Richard Jacroux | Chief Financial Officer & Secretary |
| Idan Steinberg | Head of Engineering |
| Jonathan Behr | Co-Founder |
| Scott Sober | Head of Operations |
| Ziad Rouag | Head of Regulatory & Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 425 | Filing |
| Oct 08, 2026 | 3 | Filing |
| Oct 08, 2026 | SC 13D | Filing |
| Oct 02, 2026 | S-4 | Filing |
| Oct 01, 2026 | 425 | Filing |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 25, 2026 | 425 | Filing |
| Sep 14, 2026 | 425 | Filing |
| Sep 09, 2026 | 425 | Filing |
| Sep 09, 2026 | 425 | Filing |
ENDRA Life Sciences
| Country | United States |
| IPO Date | Jun 30, 2017 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Alexander Y. Tokman |
Contact Details
3600 Green Court Ann Arbor,
Michigan 48105-1570 United States
Stock Details
| Ticker Symbol | NDRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681682 |
| CUSIP Number | 29273B500 |
| ISIN Number | US29273B5003 |
| SIC Code | 3845 |
Add to Watchlist
Select watchlists to add or remove NDRA